Should You Sell This Stock Following a Regulatory Roadblock?
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its financial results have generally been robust excluding its coronavirus antibody, whose sales are dropping.
However, every company, even the best ones, sometimes encounters headwinds. Regeneron is no exception. The drugmaker recently received a rejection letter from U.S. regulators regarding an application it submitted for one of its pipeline candidates. Let's look at what this means for the business and its shareholders.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
977,20 €
-0,18 %
Die Community zeigt großes Interesse an Regeneron Pharmaceuticals Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 1064 € für Regeneron Pharmaceuticals Inc. impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 977.2 €.
